Top NYC, NY Telehealth Companies With Best Stability & Growth (59)

Profitability: The company reports achieving annual profitability in 2023 and sustaining it, with a 2025 Rule‑of‑40 score of 51% indicating efficiency in combining growth and margin. These signals point to durable unit economics rather than growth fueled by losses.

Strong Revenue Growth: Leadership cites roughly a 30% revenue CAGR over the past three years with acceleration into 2026. Continued national marketing and expanded booking channels align with ongoing top‑line momentum.

Strategic Partnerships: New integrations—such as Blue Shield of California’s member scheduling and Yelp’s real‑time booking—extend distribution beyond the core marketplace. These moves position the platform as access infrastructure across payer and high‑intent consumer surfaces.

Investor Backing & Capital Strength: Recent Series B and Series C rounds total significant capital, signaling strong investor confidence and providing resources to scale. The company earmarks this funding to expand its clinical network, AI initiatives, and partnerships.

Strong Revenue Growth: Consistent revenue expansion since launch is highlighted by nine‑figure revenue in 2024 and statements of rapid year‑over‑year growth. Reports also note the company reached profitability in 2025 alongside continued scaling.

Strategic Partnerships: Partnerships with hundreds of health plans, employers, and health systems expand distribution and indicate payer/provider acceptance. Named collaborations (e.g., a health‑system integration) and nationwide in‑network availability broaden access and patient reach.

Strong Revenue Growth: Repeated Inc. 5000 inclusion across 2021–2025 indicates multi‑year revenue expansion, with Inc. citing an 83% three‑year growth rate for the 2025 list. These external markers collectively point to sustained top‑line momentum.

Innovation-Driven Growth: AI‑driven launches in 2026 (RethinkBH AI Dashboard and Session Note AI) demonstrate ongoing product investment intended to enhance capability and adoption. Product momentum aligns with a growth posture centered on technology advancement.

Market Expansion: The August 2025 acquisition of Joshin expands the company’s neurodiversity and disability support offering, consistent with investing for growth. Scale indicators on the official site (e.g., Fortune 100 penetration and millions of lives served) further reflect broadening market reach.

Investor Backing & Capital Strength: Back-to-back late-stage funding rounds in 2026 with a significant valuation step-up indicate strong access to capital and investor conviction. Participation from well-known venture and strategic investors underscores financing momentum.

Strong Revenue Growth: Company disclosures around the 2026 raises cite rapid year-over-year revenue gains and a growing recurring revenue base. The pace is described as compounding across multiple years.

Market Expansion: Public announcements reference service to millions of members across hundreds of organizations and recent agreements with health systems and plans. These signals point to a widening commercial footprint for an employer-focused private company.

Strong Hiring & Retention: Active hiring signals are evident with multiple recent postings across Operations, Engineering, Product, RCM, and Partnerships and a visible “We’re Hiring!” banner. Feedback suggests team size and social followership on LinkedIn are consistent with recent headcount expansion.

Market Expansion: The company markets Medicare-covered virtual psychotherapy “across all 50 states,” indicating a national footprint rather than a limited pilot. Self-described service to “thousands of patients” across many states further reinforces expanding reach.

Innovation-Driven Growth: The organization emphasizes an AI-native platform with real-time clinical insights and clinical copilots to scale care delivery and efficiency. This technology-forward posture supports growth in virtual operations for older adults.

Investor Backing & Capital Strength: Recent financing rounds, including a sizable Series B and an additional credit facility, indicate strong investor confidence and ample runway. The capital is explicitly tied to hiring, go‑to‑market, and product expansion plans across 2024–2026 communications.

Product Line Growth: Ongoing launches such as AI‑powered Claims Analytics and “Zoe for HR” suggest continued investment in expanding the platform. Added capabilities like a cash‑pay network and pharmacy‑related tools point to a broadened offering beyond core navigation.

Strategic Partnerships: Partnerships with platforms and channels such as TriNet, Workday Wellness, PrismHR, and benefit alliances indicate growing distribution reach. Event participation and partner documentation suggest active customer acquisition across employer and PEO ecosystems.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2024–2025, led by top VCs with broad participation from life/insurance strategics, indicate robust capital support for scaling. Feedback suggests this financing underpins product development and market expansion plans into 2026.

Strategic Partnerships: Named relationships with several top U.S. life insurers and new 2026 collaborations in Canada and the U.K. signal embedded distribution and enterprise validation. Company and partner announcements throughout 2025–2026 point to a steady cadence of carrier and bank integrations.

Market Expansion: Expansion from a U.S. focus into Canada and the U.K., alongside multiple 2026 partner rollouts, broadens the company’s geographic footprint. Feedback suggests these moves are increasing coverage to larger populations via insurer and financial channels.

Strong Revenue Growth: Independent private‑market researchers indicate annualized revenue rose meaningfully in 2024, showing a clear upturn driven by GLP‑1 obesity care. This reacceleration suggests business momentum returned after earlier slowdowns.

Strategic Partnerships: In April 2025, Novo Nordisk chose Ro to sell Wegovy at a lower cash price via Novo’s pharmacy channel, likely funneling incremental demand to the platform. Ongoing promotions and subscription‑style pricing through this channel indicate continued partner alignment.

Product Line Growth: Ro launched and scaled a GLP‑1 weight‑management program and published weight‑loss and lab‑improvement results supporting ongoing use and cross‑sell within its telehealth and pharmacy stack. Integration with manufacturer channels further enhanced program reach and conversion.

Investor Backing & Capital Strength: Funding announcements show Marble Health raised a $15.5M Series A in October 2025 led by Costanoa with participation from Town Hall Ventures and Khosla Ventures, signaling strong investor support. Company and investor communications indicate this capital is earmarked to scale operations, expand partnerships, and grow the team.

Market Expansion: Company updates indicate launches beyond New York into states like Ohio and New Jersey, pointing to a widening geographic footprint. Public materials also highlight school partnerships and rising therapy-session volumes since launch, consistent with expansion.

Strong Hiring & Retention: Open roles across growth, operations, and product on company and third‑party job boards indicate active team growth. Leadership posts describe go‑to‑market hiring momentum ahead of school years, suggesting sustained scaling efforts.

Strong Market Position & Advantage: Evidence indicates USPI leads the ambulatory surgery center sector by footprint and market standing, consistently referenced as the largest national platform. Industry and company descriptions highlight broad scale, procedure volume, and leadership within a consolidating yet fragmented market.

Strong Revenue Growth: Descriptions point to steady year-over-year increases in ambulatory segment revenue and earnings through 2024–2025, with raised outlooks signaling sustained momentum. Same-facility growth and higher revenue per case underscore a durable top-line trajectory.

Market Expansion: Evidence shows rapid network growth via acquisitions and de novo centers across many states and specialties. Partnerships and joint ventures with physician groups and health systems further extend geographic reach and service breadth.

Strategic Partnerships: Evidence indicates Homeward has value-based arrangements with Priority Health and Blue Cross plans in Michigan and Minnesota, plus a new statewide Meijer pharmacy collaboration to reach seniors where they shop. These partnerships expand distribution and embed the model within rural communities.

Market Expansion: The company progressed from an initial Michigan launch (2022) to Minnesota (2023) and widened to county‑level population contracts in 2024, with reported management of tens of thousands of Medicare beneficiaries and a Michigan program serving about 70,000 seniors. These moves indicate a shift from one‑by‑one enrollment to broader population health coverage.

Investor Backing & Capital Strength: Homeward raised a $50 million Series B in 2022 and was selected in 2025 for up to $12 million from ARPA‑H’s PARADIGM program. These funds signal capacity to scale operations and build out technology-enabled care in rural markets.

Strong Market Position & Advantage: Business coverage describes Maven as the largest virtual clinic/platform in women’s and family health with marquee enterprise wins like Amazon and end-to-end services across the family-health journey. Recognition such as CNBC’s Disruptor 50 and industry profiles reinforces category visibility.

Investor Backing & Capital Strength: Reports indicate a $125M Series F at a ~$1.7B valuation in October 2024, signaling staying power through a tighter funding cycle. Coverage frames this capital as supporting continued product and market expansion.

Market Expansion: The company announced a direct-to-consumer subscription in March 2026 and added distribution through health plans and marketplaces (e.g., Aetna International, Blue Cross MA, Transcarent). Global operations across many countries and growth in covered lives are also noted.